Io Biotech, Inc. (IOBT)

They are a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on their T-win technology platform. Their product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. They believe this represents a paradigm shift in the management of cancer and that their product candidates have the potential to become cornerstones of the treatment regimens of multiple solid tumors. Their lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as Indoleamine 2,3-dehydrogenase (IDO) and programmed death ligand (PD-L1). In a single-arm Phase 1/2 clinical trial (the MM1636 trial) of 30 patients with metastatic melanoma with the primary objective to investigate safety and tolerability, secondary objective to investigate immunogenicity and tertiary objective to investigate clinical efficacy, IO102-IO103, in combination with nivolumab, demonstrated an ability to induce meaningful tumor regression and establish durable antitumor response while achieving a manageable tolerability profile for patients.

Industry
Pharmaceutical Preparations

CEO	CFO
-

Employees	Founded
19	2014

Address: Mai-britt Zocca Ole Maaløes Vej 3 Dk-2200 Copenhagen N Denmark

Telephone: +45 7070 2980

Web page: http://www.iobiotech.com

First Trade Date	11/5/2021
Status	Priced
Exchange	NASDAQ
Lockup Period Expiration	.Pro
Quiet Period Expiration	.Pro
Old Price Range	-

Share prices ($)

What do you think will happen with the IOBT share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

The lead left underwriter: Morgan Stanley

Over the last 12 months Since the beginning of the year

IPOs led by the firm	.Pro
Profitability of conducted IPOs  ?	.Pro
1st day change  ?	.Pro
Change for the first 3 months  ?	.Pro

IPOs led by the firm	.Pro
Profitability of conducted IPOs  ?	.Pro
1st day change  ?	.Pro
Change for the first 3 months  ?	.Pro

Underwriters
Morgan Stanley/ Jefferies/ Cowen
CO-Managers
Kempen & Co.